The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Estrogen Therapy and Hormone Therapy are effective options for the prevention and treatment of osteoporosis, although because of their significant side effect profile, long term use for these applications is not recommended. Whereas SERMs (Selective Estrogen Receptor Modulators) exhibit a more favorable side effect profile, the currently available medicines in this class are substantially less effective in bone than classical estrogens. However, the results of substantial efforts that have gone into defining the mechanisms that underlie the pharmacology of estrogens, antiestrogens and SERMs have informed the development of the next generation of SERMs and have led to the development of TSECs (Tissue Selective Estrogen Complexes), a new class of ER-modulator. Further, the recent determination that the oxysterol 27-hydroxycholesterol functions as an endogenous SERM has highlighted an unexpected link between hypercholesterolemia and bone biology and must be considered in any discussions of ER-pharmacology. This review considers the most recent progress in our understanding of ER pharmacology and how this has and will be translated into new medicines for the treatment and prevention of osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778 · cited 1×
“This is significant in view of the recent work suggesting that osteocytes, and not osteoblasts, are the major source of the RANKL that controls osteoclastogenesis [40,41].”
BackgroundMatrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304 · cited 1×
“This is significant in view of the recent work suggesting that osteocytes, and not osteoblasts, are the major source of the RANKL that controls osteoclastogenesis [40,41].”
BackgroundEstrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.025 · Cited by 1,013
Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J.-A., & Korach, K. S. (1997) · Endocrinology · doi:10.1210/endo.138.11.5496 · Cited by 978
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“and stromal cells from postmenopausal women have been shown to express higher levels of RANKL on their surfaces [27,28].”
BackgroundFalahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“Finally, there is evidence that that 17-β estradiol suppresses both osteoblast and osteocyte apoptosis [37–39].”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“Also of note is that 17-β estradiol induces the expression and secretion of osteoprotegrin (OPG) by osteoblasts, a protein which binds to and inactivates the critical osteoclast differentiation factor, RANKL, thus inhibiting osteoclastogenesis [35].”
BackgroundRoggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513 · cited 1×
“osteoclastogenesis [25].”
Mechanisms of sex steroid effects on bone
Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380
D'Amelio, P., Grimaldi, A., Di Bella, S., Brianza, S. Z. M., Cristofaro, M. A., Tamone, C., Giribaldi, G., Ulliers, D., Pescarmona, G. P., & Isaia, G. (2008) · Bone · doi:10.1016/j.bone.2008.02.017 · Cited by 331 · cited 1×
“The relevance of this finding was highlighted in a study performed in humans which demonstrated an increase in the number of TNFα and RANKL producing T-cells in women with post-menopausal osteoporosis [26].”
BackgroundPerez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., Shenkier, T. N., Tozer, R. G., Palmer, M. J., Shepherd, L. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4882 · Cited by 307 · cited 1×
“There is substantial evidence in support of both hypotheses, although most compelling are the data showing that post-menopausal women who are taking aromatase inhibitors demonstrate an increased rate of bone loss and a significantly elevated risk of osteoporotic fracture; data which highlights the importance of non-ov…”
ResultLønning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Øfjord, E. S., Paolini, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.097 · Cited by 295
Martin-Millan, M., Almeida, M., Ambrogini, E., Han, L., Zhao, H., Weinstein, R. S., Jilka, R. L., O'Brien, C. A., & Manolagas, S. C. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0354 · Cited by 282 · cited 2×
“This was associated with an increase in osteoclast number and a corresponding decrease in trabecular bone mass [23].”
BackgroundResultKulak, J., Fischer, C., Komm, B., & Taylor, H. S. (2011) · Endocrinology · doi:10.1210/en.2010-1010 · Cited by 112
Cited by
Oxysterols: From cholesterol metabolites to key mediators
Mutemberezi, V., Guillemot-Legris, O., & Muccioli, G. G. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.002 · Cited by 335
Estrogen-Receptor Expression and Function in Female Reproductive Disease
Tang, Z.-R., Zhang, R., Lian, Z.-X., Deng, S.-L., & Yu, K. (2019) · Cells · doi:10.3390/cells8101123 · Cited by 274
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J., Krebs, T., Lim, F., Chang, C.-Y., & McDonnell, D. P. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 263
Self-citationProssnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
Selective Estrogen receptor modulators
An, K.-C. (2016) · Asian Spine Journal · doi:10.4184/asj.2016.10.4.787 · Cited by 185
Metadata
- Authors
- Nelson, E. R., Wardell, S. E., & McDonnell, D. P.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 53
- Issue
- 1
- Pages
- 42-50
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2055763885
- Cited by
- 134
- References
- 17
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.